secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-08-26T23:59:59+00:00
Accession:  0001104659-24-092626
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata reports diSArm trial 80% enrolled, AP-PA02 topline data Sep 2024; Phase 3 planned for 2025
--------------------------------------------------------------------------------

- diSArm Phase 1b/2a for AP-SA02 (S. aureus bacteremia) now 80% enrolled; completion expected Q4 2024.
- AP-PA02 (P. aeruginosa bronchiectasis) enrollment completed; topline data expected September 2024.
- Intravenous AP-SA02 and inhaled AP-PA02 well tolerated; early data show phage activity and persistence.
- Phage candidates planned to enter pivotal Phase 3 trials in 2025, supported by $21.6M DoD grant.
- Inhaled AP-PA02 monotherapy showed comparable to better bacterial load reduction vs antibiotics in blinded data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465924092626/0001104659-24-092626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465924092626/tm2422583d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-092626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer